Postoperative Nausea And Vomiting Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 2.21 Billion |
| Market Size (2029) | USD 2.88 Billion |
| CAGR (2024 - 2029) | 5.48 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Postoperative Nausea And Vomiting Market Analysis
The Postoperative Nausea And Vomiting Market size is estimated at USD 2.21 billion in 2024, and is expected to reach USD 2.88 billion by 2029, at a CAGR of 5.48% during the forecast period (2024-2029).
Postoperative nausea and vomiting (PONV) are often deemed more distressing than pain. PONV not only increases the likelihood of postoperative complications but also reduces patient comfort and satisfaction and extends hospital stays. The market is expanding and driven by a rise in trauma and surgical cases, an uptick in postoperative complications among high-risk groups, and a growing demand for combination drugs. For instance, a study published in October 2023 in the Frontiers in Pediatrics highlighted a concerning prevalence of PONV in children, ranging from 30% in the general surgical population to a staggering 80% in high-risk pediatric postoperative patients.
Similarly, research from the April 2022 edition of Anesthesia Progress Journal noted that rates of postoperative nausea and vomiting for oral surgeries ranged between 24% and 46% but surged to between 40% and 73% for orthognathic surgeries. These findings highlight the pervasive occurrence of PONV. As the frequency of surgical procedures rises, so too will the demand for drugs addressing PONV, driving the growth of the market.
The research underscores the enhanced efficacy of combination drugs in addressing postoperative nausea and vomiting. For instance, a study published in the BMC Anesthesiology in October 2023 highlighted the effectiveness of Droperidol when paired with 5-HT3 receptor antagonists in PONV prevention. Furthermore, the same source noted that adding acetaminophen, nonsteroidal anti-inflammatory drugs, and ketamine can effectively reduce opioid consumption and its side effects, including postoperative nausea and vomiting. Moreover, market players are actively exploring novel treatment therapies, seeking regulatory approvals to diversify their offerings in the PONV segment. For instance, in September 2022, Heron Therapeutics secured approval from the United States Food and Drug Administration for its APONVIE, designed to prevent PONV in adults. This move underscores the industry's dedication to broadening treatment avenues.
Thus, with the rising instances of postoperative complications, the proven efficacy of combination drugs, and the proactive measures of market players, the market is set for substantial growth in the upcoming years. However, the growing inclination towards non-invasive surgeries, which mitigate side effects like PONV and associated treatment risks, could limit the market's growth trajectory in the forecast period.
Postoperative Nausea And Vomiting Market Trends
Serotonin Antagonists Expected to Witness Significant Growth in the Market Over the Forecast Period
Some commonly used serotonin antagonists, such as ondansetron and granisetron, block serotonin receptors in the central nervous system as a preventive measure. Their established safety and efficacy in managing PONV have increasingly led physicians to favor these antagonists as a primary treatment. This growing preference has resulted in strong prescription sales, driving the segment's expansion. For instance, a February 2024 Drug, Design, Development, and Therapy Journal study highlighted findings from 141 gynecological day-case surgeries. It reported a 50.70% incidence of PONV in the flumazenil group, notably higher than the 32.86% in the control group, within 24 hours post-surgery. Such findings emphasize the prevalent need for effective PONV treatments after surgeries.
Similarly, a September 2023 study in the European Journal of Clinical Pharmacology emphasized the routine administration of Serotonin 3 receptor antagonists for patients at high risk of PONV, especially those under general anesthesia. This routine adoption is set to boost the demand for serotonin antagonists in the upcoming years.
Moreover, an April 2024 study in the British Journal of Anaesthesia highlighted the benefits of combining 5-HT3 antagonists with dexamethasone, particularly for PONV after neuraxial morphine use post-Caesarean delivery. Such insights underscore the clinical advantages and hint at opportunities for market players to introduce novel products, further fueling the demand for serotonin antagonists in PONV treatment. The serotonin antagonist segment is set for substantial growth in the coming years, given their superior safety and efficacy compared to alternative treatments and a rising interest in combination therapies.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
North America's market dominance is attributed to a confluence of factors, such as a surge in surgical procedures, an aging demographic, a robust presence of market incumbents, and a growing preference for combination drugs. Certain types of surgery, including laparoscopic, bariatric, gynecological, and cholecystectomy, may be associated with an increased risk of postoperative nausea and vomiting (PONV).
Additionally, governmental support, particularly in the form of drug reimbursement, further bolsters the adoption of these treatments. For instance, in October 2023, the Centers for Medicare & Medicaid Services (CMS) introduced a unique billing code. They granted transitional pass-through payment status for Eagle Pharmaceuticals, Inc.'s Barhemsys (amisulpride) injection. Barhemsys, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist, is designed explicitly for PONV prevention and treatment. With this initiative, patients can avail themselves of separate reimbursements for Barhemsys, easing their economic burden and, in turn, amplifying its demand trajectory.
Moreover, as the global aging population increases, the need for perioperative care will likely extend to older people. With aging come physiological changes and a higher prevalence of medical conditions, making older people more susceptible to adverse outcomes. For instance, per the latest data published by Statistics Canada, the number of persons aged 65 years and older was 7.6 million until July 2023. Furthermore, as per the data published by TD Economics in January 2023, the number of people 65 and older is projected to grow further by 1 million from the existing number by 2025. With this demographic shift, post-anesthesia care units (PACUs) will likely see a surge in geriatric patients, expanding the pool for PONV treatments.
Furthermore, key market players are actively broadening their geographical footprint, setting the stage for heightened market growth. For instance, in September 2023, Eagle Pharmaceuticals, Inc. acquired Acacia Pharma Group plc. Acacia's BARHEMSYS and BYFAVO were added to strengthen Eagle's portfolio. BARHEMSYS is indicated to treat and prevent PONV in non-prophylactic patients. Such strategic maneuvers by industry leaders are pivotal in propelling market expansion.
Hence, owing to factors such as increasing surgical procedures, rising geriatric populations with perioperative care, and strategic initiatives made by market players, North America is expected to witness growth over the forecast period.
Postoperative Nausea And Vomiting Industry Overview
The postoperative nausea and vomiting market is fragmented due to the the presence of several players. Some of these players are developing new products with fewer side effects, while others are launching generic versions of blockbuster products. The competitive landscape of the postoperative nausea and vomiting market is shaped by pharmaceutical companies, biotechnology firms, and healthcare service providers, all vying for market share in the development and commercialization of drugs, therapies, and interventions to manage postoperative nausea and vomiting. Some of the market players are Heron Therapeutics, Inc., Teva Pharmaceutical Industries Ltd, Eisai Co., Ltd., Helsinn Healthcare SA, and Novartis AG.
Postoperative Nausea And Vomiting Market Leaders
-
Heron Therapeutics, Inc.
-
Helsinn Healthcare SA
-
Teva Pharmaceutical Industries Ltd.
-
Novartis AG
-
Eisai Co., Ltd.
*Disclaimer: Major Players sorted in no particular order
Postoperative Nausea And Vomiting Market News
- April 2024: Eagle Pharmaceuticals, Inc. demonstrated the sustained efficacy of amisulpride as a rescue treatment for postoperative nausea and vomiting in its Phase III clinical trial. The company presented these findings at the 2024 National Conference of the American Society of PeriAnesthesia Nurses in Orlando, the United States.
- March 2023: Heron Therapeutics, Inc. launched Aponvie, an NK receptor antagonist in the United States. In September 2022, the United States Food and Drug Administration (FDA) approved Aponvie to prevent postoperative nausea and vomiting (PONV) in adults.
Postoperative Nausea And Vomiting Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Surgical Procedures
4.2.2 Rising Number of Trauma and Cancer Cases Coupled With the Increased Geriatric Population
4.2.3 Increased in R&D Activities and Enhanced Health Awareness Among Public
4.3 Market Restraints
4.3.1 Increasing Preference for Non-Invasive Surgeries and Risk of Complications
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Treatment Type
5.1.1 Serotonin Antagonists
5.1.2 Steroids
5.1.3 NK-1 Receptor Antagonists
5.1.4 Non-pharmacologic Treatment
5.1.5 Others
5.2 By Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Online Pharmacies
5.2.3 Retail Pharmacies and Drug Stores
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Heron Therapeutics, Inc.
6.1.2 Teva Pharmaceutical Industries Ltd.
6.1.3 Galt Pharmaceuticals (Fortovia Therapeutics Inc)
6.1.4 Helsinn Healthcare SA
6.1.5 Novartis AG
6.1.6 Merck KGaA
6.1.7 Eagle Pharmaceuticals, Inc.
6.1.8 Kyowa Kirin Inc
6.1.9 Daiichi Sankyo Company Limited (American Regent Inc)
6.1.10 Eisai Co., Ltd.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Postoperative Nausea And Vomiting Industry Segmentation
As per the scope of the report, postoperative nausea and vomiting (PONV) refer to the common occurrence of nausea, vomiting, or retching after anesthesia or within 24 hours of surgery.
The postoperative nausea and vomiting market is segmented by treatment type, distribution channel, and geography. By treatment type, the market is segmented into serotonin antagonists, steroids, NK-1 receptor antagonists, non-pharmacologic treatment, and others. The others include dopamine antagonists, anticholinergics, and others. By distribution channel, the market is segmented into hospital pharmacies, online pharmacies, retail pharmacies & drug stores. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. For each segment, the market sizing and forecasts have been done on the basis of value (USD).
| By Treatment Type | |
| Serotonin Antagonists | |
| Steroids | |
| NK-1 Receptor Antagonists | |
| Non-pharmacologic Treatment | |
| Others |
| By Distribution Channel | |
| Hospital Pharmacies | |
| Online Pharmacies | |
| Retail Pharmacies and Drug Stores |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Postoperative Nausea And Vomiting Market Research FAQs
How big is the Postoperative Nausea And Vomiting Market?
The Postoperative Nausea And Vomiting Market size is expected to reach USD 2.21 billion in 2024 and grow at a CAGR of 5.48% to reach USD 2.88 billion by 2029.
What is the current Postoperative Nausea And Vomiting Market size?
In 2024, the Postoperative Nausea And Vomiting Market size is expected to reach USD 2.21 billion.
Who are the key players in Postoperative Nausea And Vomiting Market?
Heron Therapeutics, Inc., Helsinn Healthcare SA, Teva Pharmaceutical Industries Ltd., Novartis AG and Eisai Co., Ltd. are the major companies operating in the Postoperative Nausea And Vomiting Market.
Which is the fastest growing region in Postoperative Nausea And Vomiting Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Postoperative Nausea And Vomiting Market?
In 2024, the North America accounts for the largest market share in Postoperative Nausea And Vomiting Market.
What years does this Postoperative Nausea And Vomiting Market cover, and what was the market size in 2023?
In 2023, the Postoperative Nausea And Vomiting Market size was estimated at USD 2.09 billion. The report covers the Postoperative Nausea And Vomiting Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Postoperative Nausea And Vomiting Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Postoperative Nausea And Vomiting Industry Report
Statistics for the 2024 Postoperative Nausea And Vomiting market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Postoperative Nausea And Vomiting analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
